Namita Thapar’s Emcure Pharma Investment Skyrockets 38,200% on NSE Debut

Well-known investor from Shark Tank India and Emcure Pharmaceuticals executive director Namita Thapar is seeing amazing returns on her investment as Emcure Pharma debuted on the NSE with a 31% premium. Originally ₹2.19 crore, Thapar’s initial investment in the company has now increased to a shockingly ₹671 crore after the IPO.

Beginning on the NSE at ₹1,325.05 per share, Emcure Pharmaceuticals showed a 31.45% premium over its issue price of ₹1,008. With 67.87 times of subscription, the company’s IPO—valued at ₹1,522.03 crore—generated great demand from investors. Seven times was the subscription for the retail book; the non-institutional investor (NII) section was subscribed 48 times; the qualified institutional buyers (QIBs) portion was subscribed an amazing 195 times. Thapar made about ₹127.87 crore by selling 12.68 lakh shares through the IPO’s offer-for- sale component. Reflecting a remarkable 38,200% return based on the listing price, her remaining 50.71 lakh shares now value her investment at ₹671 crore.

The IPO comprised an offer for sale of 1.14 crore shares, worth ₹1,152.03 crore, and a fresh issue of 0.79 crore shares, which comes to ₹800 crore. The price range was decided upon as ₹960 to ₹1,008 per share. Emcure had drawn ₹582.6 crore from anchor investors including Goldman Sachs, Morgan Stanley, and the Abu Dhabi Investment Authority before the IPO.

Under Link Intime India Private Limited as the registrar, Managed by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited Emcure Pharmaceuticals made a great market debut. Based in India, the company specializes in designing, manufacturing, and worldwide marketing pharmacological products covering several therapeutic spheres. Operating 13 manufacturing sites all throughout India, Emcure generates a variety of dosage forms including biotherapeutics, injectables, and orals.

Emcure’s IPO attracted strong investor interest; QIBs leading the charge subscribed 92.94 times their allocated quota. While employees showed notable interest and placed bids 7.9 times their allocated quota, non-institutional investors bought up 42.57 times the reserved amount. Retail investors purchased shares set aside for them 6.33 times over. Share allocation was decided upon on July 8; Emcure Pharma shares were listed on the BSE and NSE on July 10.

Having products in more than 70 countries, Emcure Pharmaceuticals is somewhat well-known worldwide. Oral solids, oral liquids, injectables, and sophisticated active pharmaceutical ingredients (APIs) including chiral molecules, iron molecules, and cytotoxic goods comprise the company’s product line. Emcure’s successful IPO shows great investor trust in the company’s expansion possibilities and pharmaceutical sector posture, despite market turbulence.

Disclaimer: Business Today should not be used as investment advice; it offers stock market news for informational only reasons. Before deciding on any investment, readers are advised to speak with a certified financial adviser.